Pharmaceutical company
Appears in 5 stories
Sponsor of camizestrant (NDA 220359) and Truqap (sNDA 218197/S-004)
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated May 31
Maker of osimertinib (Tagrisso), the drug whose resistance the models replicate
Every year, hundreds of thousands of lung cancer patients start treatment with osimertinib, the leading targeted therapy for tumors driven by mutations in the EGFR gene. Most will respond, but nearly all will eventually stop responding as their cancers evolve resistance through a dozen different molecular escape routes. Until now, researchers had to work with messy lab models that made it hard to pin down which genetic change caused which failure.
Manufacturer of acalabrutinib (Calquence); sponsor of the AMPLIFY trial
On February 20, 2026, the FDA approved venetoclax and acalabrutinib for chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western countries, with roughly 23,000 new American cases each year. In a trial of 867 patients, 77% remained cancer-free at three years.
Updated May 29
Developing AI-powered oncology drug development infrastructure
For decades, cancer drug trials have failed at a rate exceeding 95%, burning through $50–60 billion annually on treatments tested in patients unlikely to respond. On April 17, 2025, researchers from AstraZeneca and Tempus AI published in Cancer Cell results from the Predictive Biomarker Modeling Framework, a machine learning system using contrastive learning on existing clinical data. The system can identify which cancer patients will survive longer on immunotherapy versus chemotherapy. Applied retrospectively to completed phase 3 trials, it improved survival outcomes by 15% compared to traditional patient selection.
Updated May 27
Co-commercializes Enhertu with Daiichi Sankyo; lead promoter in the U.S. market
The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.
Updated May 18
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
